EGFR and non-small cell lung carcinoma: Subsequently, an international, phase 3, open-label study (EXCLAIM-2) compared first-line mobocertinib treatment to platinum-based chemotherapy in patients with locally advanced/metastatic NSCLC positive for EGFR exon 20 insertion mutations [31].